Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Emiltatug Ledadotin (Emi-Le, XMT-1660)

Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)

Servier (registry sponsor Day One Biopharmaceuticals) · Phase 1/2 · Recruiting · Enrollment 360

NCT05377996

Catalyst Primary completion. 02.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst EMBLEM-1 first patients dosed. 10.19.2026. Company release; event occurred.

ArmReported safety
Emi-Le, ACC efficacy cohortn/r
Emi-Le, post hoc aggressive subtypen/r
Emi-Le, ACC safety cohortgrade 3 treatment-related adverse events: 79.2%, ASCO 2026treatment-related discontinuation: 2.1%, ASCO 2026dose reduction: 45.8%, ASCO 2026
EMBLEM-1 pivotal Phase 2 cohortn/r

A count stays a count. This page does not turn a count into a percent.